← The Wire
AVTXNasdaq
Avalo Therapeutics, Inc.
Pharmaceutical Preparations · DE · CIK 1534120
Developing IL-1β-based treatments for immune-mediated inflammatory diseases, including their lead candidate abdakibart for hidradenitis suppurativa
red 8-K · 90d
$776M
Market cap
$19.29
Last close
+6.0%
1D
+12.9%
5D
1.6M
Volume
Price · last 39 sessions+40.0%
May 4L $12.74 · H $22.87Jun 29
300
Total filings
Jun 23, 2026
Last filing
12/31
Fiscal year end
DEF 14ADEF 14AApr 10, 2026DEF 14ADEF 14AMay 1, 2025DEF 14ADEF 14AJun 27, 2024DEF 14ADEF 14AOct 19, 2023DEF 14ADEF 14AApr 25, 2022DEF 14ADEF 14AApr 27, 2021DEF 14ADEF 14AApr 28, 2020DEF 14ADEF 14AJun 19, 2019DEF 14ADEF 14AApr 5, 2018DEF 14ADEF 14AMar 31, 2017
Insider Activity
In the 90 days to Mar 16, 2026: 1 sold $412K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 16, 2026 | Doyle MittieChief Medical Officer | Sell | 25,492 | $16.15 | $412K |
| Nov 14, 2025 | Goldman JonathanDirector | Sell | 8,200 | $14.35 | $118K |
| Nov 14, 2025 | Goldman JonathanDirector | Sell | 3,167 | $14.30 | $45K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance